Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

1.

HIV vaccine design: the neutralizing antibody conundrum.

Stamatatos L.

Curr Opin Immunol. 2012 Jun;24(3):316-23. doi: 10.1016/j.coi.2012.04.006. Epub 2012 May 15. Review. No abstract available.

PMID:
22595693
[PubMed - indexed for MEDLINE]
2.

Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?

Montefiori DC, Mascola JR.

Curr Opin HIV AIDS. 2009 Sep;4(5):347-51. doi: 10.1097/COH.0b013e32832f4a4d. Review.

PMID:
20048696
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Kwong PD, Mascola JR, Nabel GJ.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007278. doi: 10.1101/cshperspect.a007278. Review.

PMID:
22229123
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Emerging concepts on the role of innate immunity in the prevention and control of HIV infection.

Ackerman ME, Dugast AS, Alter G.

Annu Rev Med. 2012;63:113-30. doi: 10.1146/annurev-med-050310-085221. Epub 2011 Nov 8. Review.

PMID:
22077718
[PubMed - indexed for MEDLINE]
5.

"Rational vaccine design" for HIV should take into account the adaptive potential of polyreactive antibodies.

Dimitrov JD, Kazatchkine MD, Kaveri SV, Lacroix-Desmazes S.

PLoS Pathog. 2011 Jun;7(6):e1002095. doi: 10.1371/journal.ppat.1002095. Epub 2011 Jun 16. Review. No abstract available.

PMID:
21698229
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

A Blueprint for HIV Vaccine Discovery.

Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R.

Cell Host Microbe. 2012 Oct 18;12(4):396-407. doi: 10.1016/j.chom.2012.09.008. Review.

PMID:
23084910
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

Verkoczy L, Kelsoe G, Moody MA, Haynes BF.

Curr Opin Immunol. 2011 Jun;23(3):383-90. doi: 10.1016/j.coi.2011.04.003. Epub 2011 Apr 27. Review.

PMID:
21524897
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Neutralizing antibodies to HIV-1 induced by immunization.

McCoy LE, Weiss RA.

J Exp Med. 2013 Feb 11;210(2):209-23. doi: 10.1084/jem.20121827. Review.

PMID:
23401570
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.

Koff WC.

Vaccine. 2012 Jun 19;30(29):4310-5. doi: 10.1016/j.vaccine.2011.11.014. Epub 2011 Nov 17. Review.

PMID:
22100891
[PubMed - indexed for MEDLINE]
10.

Neutralizing antibodies and control of HIV: moves and countermoves.

Hessell AJ, Haigwood NL.

Curr HIV/AIDS Rep. 2012 Mar;9(1):64-72. doi: 10.1007/s11904-011-0105-5. Review.

PMID:
22203469
[PubMed - indexed for MEDLINE]
11.

Role of humoral immunity in host defense against HIV.

Baum LL.

Curr HIV/AIDS Rep. 2010 Feb;7(1):11-8. doi: 10.1007/s11904-009-0036-6. Review.

PMID:
20425053
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Is developing an HIV-1 vaccine possible?

Haynes BF, Liao HX, Tomaras GD.

Curr Opin HIV AIDS. 2010 Sep;5(5):362-7. doi: 10.1097/COH.0b013e32833d2e90. Review.

PMID:
20978375
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Rational antibody-based HIV-1 vaccine design: current approaches and future directions.

Walker LM, Burton DR.

Curr Opin Immunol. 2010 Jun;22(3):358-66. doi: 10.1016/j.coi.2010.02.012. Epub 2010 Mar 17. Review.

PMID:
20299194
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.

Wren L, Kent SJ.

Hum Vaccin. 2011 Apr;7(4):466-73. Epub 2011 Apr 1. Review.

PMID:
21389779
[PubMed - indexed for MEDLINE]
Free Article
15.

HIV/AIDS vaccines: 2007.

Robinson HL.

Clin Pharmacol Ther. 2007 Dec;82(6):686-93. Epub 2007 Oct 31. Review.

PMID:
17971817
[PubMed - indexed for MEDLINE]
16.

B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design.

Cagigi A, Nilsson A, De Milito A, Chiodi F.

Vaccine. 2008 Jun 6;26(24):3016-25. doi: 10.1016/j.vaccine.2007.11.063. Epub 2007 Dec 17. Review.

PMID:
18164520
[PubMed - indexed for MEDLINE]
17.

The design and evaluation of HIV-1 vaccines.

Saunders KO, Rudicell RS, Nabel GJ.

AIDS. 2012 Jun 19;26(10):1293-302. doi: 10.1097/QAD.0b013e32835474d2. Review.

PMID:
22706011
[PubMed - indexed for MEDLINE]
18.

The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility.

Korber B, Gnanakaran S.

Curr Opin HIV AIDS. 2009 Sep;4(5):408-17. doi: 10.1097/COH.0b013e32832f129e. Review.

PMID:
20048705
[PubMed - indexed for MEDLINE]
19.

The role of antibodies in HIV vaccines.

Mascola JR, Montefiori DC.

Annu Rev Immunol. 2010;28:413-44. doi: 10.1146/annurev-immunol-030409-101256. Review.

PMID:
20192810
[PubMed - indexed for MEDLINE]
20.

Non-neutralizing antibodies in prevention of HIV infection.

Robinson HL.

Expert Opin Biol Ther. 2013 Feb;13(2):197-207. doi: 10.1517/14712598.2012.743527. Epub 2012 Nov 6. Review.

PMID:
23130709
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk